Published in Blood on June 15, 1995
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell (2012) 2.08
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov (2013) 1.93
Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell (2010) 1.92
The hematopoietic stem cell niche--home for friend and foe? Cytometry B Clin Cytom (2012) 1.70
JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood (2014) 1.08
Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells. Leukemia (2010) 1.03
Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Mol Cancer (2010) 1.00
Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood (2007) 0.97
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol (2010) 0.96
A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells. Blood (2011) 0.96
Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene (2015) 0.92
A novel role for the marrow microenvironment in initiating and sustaining hematopoietic disease. Expert Opin Biol Ther (2009) 0.87
Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors. Leukemia (2010) 0.85
Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia. Clin Epigenetics (2011) 0.81
Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDS. Curr Cancer Ther Rev (2009) 0.79
Effect of intravenous coadministration of human stroma cell lines on engraftment of long-term repopulating clonal myelodysplastic syndrome cells in immunodeficient mice. Blood Cancer J (2013) 0.78
Assessment of interleukin 1β serum level in different responder groups and stages of chronic myeloid leukemia patients on imatinb mesylate therapy. Indian J Hematol Blood Transfus (2014) 0.75
Surface morphology of leukemic cells from chronic myeloid leukemia under atomic force microscopy. Curr Health Sci J (2013) 0.75
Quantitative analysis of glycans, related genes, and proteins in two human bone marrow stromal cell lines using an integrated strategy. Exp Hematol (2015) 0.75
Detection of BCR/ABL Translocation in Bone Marrow Derived Mesenchymal Stem Cells in Egyptian CML Patients. Open Access Maced J Med Sci (2015) 0.75
Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI. Blood (2016) 0.75
TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia (2016) 0.75
Quantification of clonal hematopoiesis in polycythemia vera. Virchows Arch (2005) 0.75
Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. J Cancer Res Clin Oncol (2011) 0.75
CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med (2001) 3.51
Retracted Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood (2001) 3.46
Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant (2008) 2.86
FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res (2006) 2.41
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia (2003) 2.28
Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood (2001) 2.15
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol (2001) 2.10
Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest (1998) 2.06
Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am J Transplant (2011) 1.96
True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases. Blood (1995) 1.81
Cytogenetic analysis of six renal oncocytomas and a chromophobe cell renal carcinoma. Evidence that -Y, -1 may be a characteristic anomaly in renal oncocytomas. Cancer Genet Cytogenet (1992) 1.73
Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med (1988) 1.73
p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med (2000) 1.73
Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood (1988) 1.72
Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells. Ann N Y Acad Sci (2001) 1.72
Homeostatic expansion occurs independently of costimulatory signals. J Immunol (2001) 1.70
The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood (1985) 1.67
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer (1997) 1.63
Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study. Bone Marrow Transplant (2006) 1.63
Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J Immunol (1999) 1.61
Dual color fluorescence in situ hybridization to investigate aneuploidy in sperm from 33 normal males and a man with a t(2;4;8)(q23;q27;p21) Fertil Steril (1994) 1.54
Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia. Int J Radiat Oncol Biol Phys (1995) 1.53
Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med (2001) 1.51
Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. Am J Transplant (2014) 1.50
A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant (2000) 1.48
Phenotypical and functional characterization of intrahepatic bile duct cells from common duct ligated mice. J Lab Clin Med (1996) 1.47
Male donor-derived cells in the brains of female sex-mismatched bone marrow transplant recipients: a Y-chromosome specific in situ hybridization study. J Neuropathol Exp Neurol (1993) 1.46
WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia (2005) 1.44
Studies on the liver to kidney switch of erythropoietin production. J Clin Invest (1981) 1.41
In vivo administration of recombinant human granulocyte/macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts. Blood (1989) 1.40
Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells. Blood (1998) 1.39
Autologous bone marrow transplantation in non-Hodgkin's lymphoma: monoclonal antibodies plus complement for ex vivo marrow treatment. Am J Med (1988) 1.39
Long-term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet (1993) 1.38
Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood (1990) 1.38
Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma. Br J Haematol (2000) 1.38
Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest (1992) 1.36
A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet (1998) 1.34
Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood (2001) 1.33
B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia (2002) 1.32
Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alterations in their interaction with fibronectin. J Exp Med (1991) 1.30
In vivo chloroquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance. Diabetes (1984) 1.30
Physical mapping of a translocation breakpoint in neurofibromatosis. Science (1989) 1.27
Factors predicting single-unit predominance after double umbilical cord blood transplantation. Bone Marrow Transplant (2011) 1.26
Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood (1998) 1.25
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report. J Pediatr Hematol Oncol (2001) 1.24
Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia (2002) 1.23
IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant (2003) 1.22
Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine (Baltimore) (1989) 1.22
Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transplant (2009) 1.21
The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and potentiated by cyclophosphamide. J Clin Invest (1997) 1.19
Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant (1992) 1.18
Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. Transplantation (1993) 1.18
Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant (2001) 1.18
A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med (1982) 1.18
Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol (2001) 1.17
Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study. Leukemia (2001) 1.17
Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia. Br J Haematol (2005) 1.16
Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. Blood (1998) 1.15
Varying intensity of postremission therapy in acute myeloid leukemia. Blood (1992) 1.13
Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. Transplantation (1987) 1.13
Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation. J Clin Invest (1995) 1.13
Acute myeloid leukemia with minimal differentiation. A multiple parameter study. Am J Clin Pathol (1998) 1.13
Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood (1986) 1.12
A tdic(5;15)(p31;p11) chromosome showing variation for constriction in the centromeric regions in a patient with the cri du chat syndrome. Cytogenet Cell Genet (1979) 1.12
The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders. Cancer Genet Cytogenet (1985) 1.12
Stem and progenitor cells for liver repopulation: can we standardise the process from bench to bedside? Gut (2008) 1.12
Chromosomally abnormal clones and nonrandom telomeric translocations in cardiac myxomas. Mayo Clin Proc (1987) 1.11
A cytogenetic study of 53 human gliomas. Cancer Genet Cytogenet (1989) 1.11
Umbilical cord blood cells capable of engrafting in primary, secondary, and tertiary xenogeneic hosts are preserved after ex vivo culture in a noncontact system. Blood (2001) 1.10
The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol (2000) 1.10
New strategies for preventing graft-versus-host disease. Curr Opin Immunol (1999) 1.10
Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation (1994) 1.10
Invasive Fusarium infections in bone marrow transplant recipients. Am J Med (1984) 1.10
High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant (2010) 1.09
Frequent occurrence of cytogenetic abnormalities in sporadic nonmedullary thyroid carcinoma. Cancer (1990) 1.09
Outcome of dialysis for acute renal failure in pediatric bone marrow transplant patients. Bone Marrow Transplant (1994) 1.08
Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function. J Clin Invest (1994) 1.06
Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation. Biol Blood Marrow Transplant (2001) 1.06
Cytokine expression in human cutaneous chronic graft-versus-host disease. Bone Marrow Transplant (1996) 1.06
Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet (1984) 1.06
Extrinsic risk factors for pneumonia in the patient at high risk of infection. Am J Med (1984) 1.06
Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet (1999) 1.05
Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. J Immunol (1999) 1.04
Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia (2001) 1.04
Regulation of glutathione redox status in lung and liver by conditioning regimens and keratinocyte growth factor in murine allogeneic bone marrow transplantation. Transplantation (2001) 1.04
Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood (2001) 1.04
Stromal fibroblast heparan sulfate is required for cytokine-mediated ex vivo maintenance of human long-term culture-initiating cells. Blood (1996) 1.04
Hemotherapy in patients undergoing blood group incompatible bone marrow transplantation. Transfusion (1983) 1.04